Skip to main content
. Author manuscript; available in PMC: 2014 Mar 26.
Published in final edited form as: J Immunotoxicol. 2010 Aug 24;7(4):298–307. doi: 10.3109/1547691X.2010.509289

Figure 4.

Figure 4

Confirmation of ERK/p38 pathway involvement in WTC2.5-induced IL-6 formation. BEAS-2B cells were pre-treated with PD98059 (ERK inhibitor) or SB203580 (p38 kinase inhibitor) for 1 hr and then exposed to WTC2.5 (100 μg/ml) along with the MAPK pathway inhibitors for 5 hr (in 0.5 ml total volumes). Results are expressed as mean ± SD. *Indicates a statistically significant change (p < 0.05) when compared to value for DMSO-treated samples; **indicates significant change (p < 0.05) when compared to value for DMSO-WTC2.5 samples. Values shown are mean relative cytokine level vs. that in DMSO control cultures (± SD) from three replicate cultures.